|
9th Influenza Conference 2023
Scientific highlights of the 9th ESWI Influenza Conference
With promising developments in the field of respiratory viral infections, the conference sessions covered hot topics on seasonal, pandemic, and zoonotic influenza viruses, as well as other respiratory viruses such as RSV and SARS-CoV-2.
XBB.1.5 monovalent mRNA vaccine booster elicits robust neutralizing antibodies against XBB subvariants and JN.1
COVID-19 vaccines have recently been updated to specifically encode or contain the spike protein of the SARS-CoV-2 XBB.1.5 subvariant.
Perception of government performance during COVID-19 not linked to death rate.
People living in the United States are more likely to report that their government handled the COVID-19 pandemic ‘well’ than any other G7 nation despite having the highest death rate, according to a new report from the Global Listening Project.
Mucosal and systemic immune correlates of viral control after SARS-CoV-2 infection challenge in seronegative adults
Human infection challenge permits in-depth, early, and pre-symptomatic characterization of the immune response, enabling the identification of factors that are important for viral clearance.
WHO Information Network for Epidemics update on COVID-19
Latest information about circulation, impact and what is needed to prevent infections, severe disease, post-COVID-19 condition and deaths.
Is it bad, is it good, or is IgG4 just misunderstood?
Repeated doses of mRNA vaccines for COVID-19 result in increased proportions of anti-spike antibodies of the IgG4 subclass.
Scientific Papers
News
Article
Omicron BA.2 breakthrough infection elicits CD8+ T cell responses recognizing the spike of later Omicron subvariants
Recent studies have suggested that memory T cells play a critical role in protecting individuals immunized with SARS-CoV-2 vaccines against variants
Antigenicity and receptor affinity of SARS-CoV-2 BA.2.86 spike
The European Respiratory Virus Surveillance Summary (ERVISS)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and severe acute respiratory syndrome coronavirus 2 for the EU/EEA and the WHO European Region
SARS-CoV-2 evolution in the Omicron era
Since SARS-CoV-2 BA.5 (Omicron) emerged and spread in 2022, Omicron lineages have markedly diversified.
The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research
In the last three years, extensive research has demonstrated the safety and efficacy of COVID-19 vaccines. These vaccines have played a critical role in reducing mortality and hospitalization rates.
Variant-adapted COVID-19 booster vaccines
Current vaccines should be tailored to combat future SARS-CoV-2 variants.